State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company's programs, including a new one to come
He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs.









.png)